Gottlieb Calls On Congress To Act On US Biosimilars Uptake
Calls to give up on biosimilars in the US are premature, former FDA commissioner Scott Gottlieb insists. Rather, he says, Congress should act to promote uptake and greater competition in the biologics arena.
You may also be interested in...
CDER director lobbied for inclusion of a 505(b)(2)-like category for biologics, but it was ultimately not included in the 2010 legislation creating the biosimilar pathway; Woodcock urges patience on the development of the biosimilar marketplace and notes the agency will be keeping an eye on the development of biobetters, which are relatively new innovations.
Promoting the use of biosimilars among their employees to whom they provide health insurance could reduce their costs for specialty drugs by more than a tenth, an analysis of real-world claims data suggests.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.